Stock analysts at Royal Bank Of Canada assumed coverage on shares of Clovis Oncology, Inc. (NASDAQ:CLVS) in a research note issued to investors on Thursday, The Fly reports. The brokerage set a “sector perform” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Cann assumed coverage on Clovis Oncology in a research note on Thursday, June 22nd. They issued a “market perform” rating for the company. Evercore ISI assumed coverage on Clovis Oncology in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 price objective for the company. Leerink Swann lowered their price objective on Clovis Oncology to $107.00 and set an “outperform” rating for the company in a research note on Friday, August 18th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 18th. Finally, BidaskClub raised Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Nine equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Clovis Oncology currently has an average rating of “Buy” and a consensus target price of $85.16.

Clovis Oncology (NASDAQ:CLVS) traded down 1.14% during trading on Thursday, hitting $69.97. The stock had a trading volume of 793,117 shares. Clovis Oncology has a 12 month low of $25.50 and a 12 month high of $99.45. The stock’s market cap is $3.42 billion. The stock has a 50 day moving average price of $75.80 and a 200-day moving average price of $68.70.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The firm had revenue of $14.62 million during the quarter, compared to analyst estimates of $13.07 million. Clovis Oncology’s revenue was down 32.5% on a year-over-year basis. During the same period last year, the firm earned ($2.07) earnings per share. On average, equities analysts predict that Clovis Oncology will post ($7.53) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/14/clovis-oncology-inc-clvs-now-covered-by-royal-bank-of-canada.html.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $91.56, for a total transaction of $274,680.00. Following the transaction, the insider now directly owns 197,583 shares in the company, valued at approximately $18,090,699.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James C. Blair sold 18,450 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $78.61, for a total value of $1,450,354.50. Following the transaction, the director now owns 2,185 shares in the company, valued at $171,762.85. The disclosure for this sale can be found here. Insiders have sold a total of 24,450 shares of company stock worth $1,935,185 over the last 90 days. 17.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nationwide Fund Advisors increased its holdings in shares of Clovis Oncology by 11.7% in the 1st quarter. Nationwide Fund Advisors now owns 42,870 shares of the biopharmaceutical company’s stock valued at $2,730,000 after acquiring an additional 4,485 shares during the period. Shell Asset Management Co. purchased a new position in shares of Clovis Oncology in the 1st quarter valued at $489,000. Strs Ohio purchased a new position in shares of Clovis Oncology in the 1st quarter valued at $896,000. Russell Investments Group Ltd. purchased a new position in shares of Clovis Oncology in the 1st quarter valued at $1,890,000. Finally, Canada Pension Plan Investment Board increased its holdings in shares of Clovis Oncology by 22.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 50,300 shares of the biopharmaceutical company’s stock valued at $3,203,000 after acquiring an additional 9,200 shares during the period. Institutional investors own 98.94% of the company’s stock.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

The Fly

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.